Antoni Ribas, MD discusses cancer drugs targeting the PD1 signaling pathways

March 19, 2013- Interviewed by Steven E. Greer, MD

The upcoming ASCO meeting will be dominated by numerous presentations relating to new cancer drugs targeting the cell surface molecule called PD-L1, and the immune cell receptors PD1. Early Phase 1 data in non-small cell lung cancer, renal cancer, and melanoma demonstrated such impressive sustained tumor responses that they papers were published in the New England Journal of Medicine. Antoni Ribas, MD of the UCLA Jonsson Comprehensive Cancer Center is involved in trials testing some of these new molecules. In the video interview, he explains the mechanisms of action, reviews data published so far, and previews new data to be seen at ASCO.

This entry was posted in - Biotech, - Pharma, Oncology, UCLA. Bookmark the permalink.

Leave a Reply

Your email address will not be published.